Myriad Genetics (MYGN) shares were down 7.5% in recent Wednesday trading after Scotiabank downgraded the stock to sector perform from sector outperform and adjusted its price target to $6 from $20.
Trading volume stood at over 970,000 shares compared with a daily average of about 1.9 million.
Price: 4.12, Change: -0.34, Percent Change: -7.53